
Changes in the history of breast carcinoma -Subclinical lesions: breast conservation therapy -Sentiael lymph node -Different therapeutic options: prognostic, predictive factors and targeted therapy Diagnosis Pathology Prognosis]
Changes in the history of breast carcinoma - Subclinical lesions: breast conservation therapy - Sentinel lymph node - Different therapeutic options: prognostic, predictive factors and targeted therapy		
Changes in the history of breast carcinoma - Subclinical lesions: breast conservation therapy - Sentinel lymph node - Different therapeutic options: prognostic, predictive factors and targeted therapy		
Changes in the history of breast carcinoma - Subclinical lesions: breast conservation therapy - Sentinel lymph node - Different therapeutic options: prognostic, predictive factors and targeted therapy		
Changes in the history of breast carcinoma -Subclinical lesions: breast conservation therapy -Sentinel lymph node -Different therapeutic options: prognostic, predictive factors and targeted therapy	Current Update on Conservation Therapy:	
Changes in the history of breast carcinoma -Subclinical lesions: breast conservation therapy -Sentinel lymph node -Different therapeutic options: prognostic, predictive factors and targeted therapy	Evaluation of the Dathology engineer	
Changes in the history of breast carcinoma -Subclinical lesions: breast conservation therapy -Sentinel lymph node -Different therapeutic options: prognostic, predictive factors and targeted therapy	Evaluation of the Pathology specimen	
Changes in the history of breast carcinoma -Subclinical lesions: breast conservation therapy -Sentinel lymph node -Different therapeutic options: prognostic, predictive factors and targeted therapy		
Changes in the history of breast carcinoma -Subclinical lesions: breast conservation therapy -Sentinel lymph node -Different therapeutic options: prognostic, predictive factors and targeted therapy		
Changes in the history of breast carcinoma *Subclinical lesions: breast conservation therapy *Sentinel lymph node *Different therapeutic options: prognostic, predictive factors and targeted therapy		
*Subclinical lesions: breast conservation therapy *Sentinel lymph node *Different therapeutic options: prognostic, predictive factors and targeted therapy	Thomas Jefferson University	-
*Subclinical lesions: breast conservation therapy *Sentinel lymph node *Different therapeutic options: prognostic, predictive factors and targeted therapy		
*Subclinical lesions: breast conservation therapy *Sentinel lymph node *Different therapeutic options: prognostic, predictive factors and targeted therapy		
*Subclinical lesions: breast conservation therapy *Sentinel lymph node *Different therapeutic options: prognostic, predictive factors and targeted therapy		
*Subclinical lesions: breast conservation therapy *Sentinel lymph node *Different therapeutic options: prognostic, predictive factors and targeted therapy		
*Subclinical lesions: breast conservation therapy *Sentinel lymph node *Different therapeutic options: prognostic, predictive factors and targeted therapy		1
*Subclinical lesions: breast conservation therapy *Sentinel lymph node *Different therapeutic options: prognostic, predictive factors and targeted therapy		
*Subclinical lesions: breast conservation therapy *Sentinel lymph node *Different therapeutic options: prognostic, predictive factors and targeted therapy		
*Sentinel lymph node *Different therapeutic options: prognostic, predictive factors and targeted therapy	Changes in the history of breast carcinoma	
*Sentinel lymph node *Different therapeutic options: prognostic, predictive factors and targeted therapy		
*Sentinel lymph node *Different therapeutic options: prognostic, predictive factors and targeted therapy		
*Different therapeutic options: prognostic, predictive factors and targeted therapy	therapy	
predictive factors and targeted therapy	•Sentinel lymph node	
predictive factors and targeted therapy	Different thereneutic entions: prognectic	
. — Pathology — .	predictive factors and targeted therapy	
Diagnosis — Pathology — Prognosis		
Diagnosis Prognosis		
Diagnosis Prognosis		
Diagnosis Prognosis		
Diagnosis Prognosis		
Diagnosis Prognosis		
Diagnosis Prognosis		1
Diagnosis Prognosis		
Diagnosis Prognosis	Pathology	
	Diagnosis Prognosis	
	-	



Classic prognostic factors

- Size
- Type of tumor
- Nuclear and histologic grades
- Mitotic index
- Vascular invasion
- Margins
- Lymph nodes (SLN)

Size: Macroscopic and microscopic determination

Microscopic examination:
Type of tumor
Nuclear and histologic grades
Mitotic index
Vascular invasion
Margins
Lymph nodes (SLN)

Fixation issues	
•Time elapsed between biopsy and fixation.	
•Type of fixative and time of fixation: avoid the	
friday afternoon effect	
Sampling of the biopsy	
•Enough sections to evaluate the important parameters for BCT	
•Targeted sampling of the biopsy if too large	
 If core biopsy shows certain features, more sampling maybe necessary: special type of cancer, inflammatory cancer, Paget's disease 	
Sample macroscopically uninvolved tissue: LVI, lobular cancer, precursor lesions	
precursor resions	
Size	
 Size is not a limiting factor for BCT 	
•Ratio of tumor size/breast size important	

Size


- •Close correlation with imaging
- Macroscopic and microscopic measurement
- Pitfalls : invasive component, fragmented biopsies, lobular cancer

Tumor type

Important when considering breast conservation therapy

Uctal Lobular Tubulolobular Special types

Special types of cancer




Better outcome, but strict diagnostic criteria

Grade High grade Low grade Tubule formation Nuclear grade Mitotic rate


Margins


- Orientation and x ray of the specimen
- •Sampling of margins: to freeze or not to freeze
- Reporting of margins
- •Significance of the number of positive margins
- Margin status in relation to tumor type and size



Assessment of margins

- •Shaved margins
- Perpendicular margins: allows reporting of the distance from the tumor to the margin
- Volume of tumor near the margin: size and location of the tumor





Evaluation of margins: residual cancer

- •276 patients: 32% close (53%),61% positive (68%) and 7% undetermined margins (67%)
- •Increased incidence: large size, higher grade, positive margins (number of margins involved), single inked markings, young age

Cellini Ann Surg Oncol 11:915,2004

Adverse findings that need to be reported

- •Positive margins
- •High grade cancers
- •High mitotic rate
- Necrosis
- •Vascular invasion
- •Extensive intraductal component
- Multicentricity

Risk stratification according to pathological

parameters:

Size

Margins

Tumor type

Grade

Vascular invasion

Multicentricity/EIC

Poor prognosis

Good prognosis

Intermediate



- 68	C	3			۲.
,	r		b	Z	
			٦	ч	7



